4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication - Archive ouverte HAL
Article Dans Une Revue Science Année : 2022

4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication

Julien Sourimant
Josef Wolf
Jeong-Joong Yoon
Richard Plemper

Résumé

Preparing antiviral defenses Antiviral drugs are an important tool in the battle against COVID-19. Both remdesivir and molnupiravir, which target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase, were first developed against other RNA viruses. This highlights the importance of broad-spectrum antivirals that can be rapidly deployed against related emerging pathogens. Sourimant et al . used respiratory syncytial virus (RSV) as a primary indication in identifying further drugs that target the polymerase enzyme of RNA viruses. The authors explored derivatives of molnupiravir and identified 4′ fluorouridine (EIDD-2749) as an inhibitor of the polymerase of RSV and SARS-CoV-2. This drug can be delivered orally and was effective against RSV in mice and SARS-CoV-2 in ferrets. —VV

Dates et versions

hal-04673889 , version 1 (20-08-2024)

Identifiants

Citer

Julien Sourimant, Carolin Lieber, Megha Aggarwal, Robert Cox, Josef Wolf, et al.. 4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science, 2022, 375 (6577), pp.161-167. ⟨10.1126/science.abj5508⟩. ⟨hal-04673889⟩
27 Consultations
0 Téléchargements

Altmetric

Partager

More